Sector News

Tokai Pharmaceuticals takes ax to 60% of workforce

August 2, 2016
Life sciences

A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly announced major cuts across its company.

In total, Tokai will cull its workforce by around 60% to a total of 10 “full-time equivalent employees,” according to its statement, with this bloodletting expected to be complete by the end of the third quarter.

The Boston, MA-based company posted data last week showing that its experimental cancer med galeterone was likely not to best Astellas/Medivation’s Xtandi (enzalutamide) in a Phase III trial.

On the recommendation of its data monitoring committee, which said it would be a flop, the biotech discontinued that pivotal trial due to disappointing data. Tokai shares tumbled by about 70% on the news last week.

The company had other studies lined up, including its ARMOR2 expansion in metastatic castration-resistant prostate cancer (mCRPC) for patients with acquired resistance to Xtandi, and also a planned test in patients who rapidly progress on either Xtandi or Janssen’s prostate cancer drug Zytiga (abiraterone acetate). The future of these trials is, however, uncertain.

In a brief statement, the biotech said: “This workforce reduction is designed to reduce operating expenses while the company conducts a comprehensive evaluation of strategic options for galeterone and its pipeline. Affected employees are being offered severance and outplacement assistance.”

The biotech hopes to save $4.2 million as a result of the cuts, although it will absorb a third-quarter charge of $1.3 million in severance costs for its former staffers.

“A reduction in force is a very difficult yet necessary step in light of the recent discontinuation of the ARMOR3-SV trial of galeterone in mCRPC,” said Jodie Morrison, president and CEO of Tokai.

“I would like to personally express my appreciation to each of the employees impacted by this decision for their commitment to the development of galeterone, as well as for their meaningful contributions to a program that has expanded the dialogue among the medical and patient communities about AR-V7 and advanced prostate cancer treatment options.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach